CAR-T Characterization Panel
Helping Your Research
The nCounter CAR-T Characterization Panel was created in collaboration with experts in CAR-T therapy to facilitate the development of robust product release assays. Confidently profile CAR-T products for research and manufacturing applications with an automated, and reproducible assay. Ideally suited for new CAR-T development and QC, the CAR-T Characterization Gene Expression Panel can help streamline the CAR-T manufacturing workflow and potentially reduce vein to vein time. This panel can measure eight essential components of CAR-T biology with 780 human genes.
Empower your knowledge of CAR-T with the most up-to-date biology developed with experts in the field.
- Optimize CAR-T method development
- Create manufacturing acceptance criteria
- Measure metabolic fitness and persistence
- Monitor post-infusion exhaustion and toxicity
How It Works
CAR-T Therapy Workflow
Understanding each step of the CAR-T workflow is critical to ensuring quality and efficacy of the final CAR-T product. The nCounter CAR-T Characterization Panel can be used throughout development and manufacturing as a standardized panel of genes for optimizing methods, developing manufacturing acceptance criteria as well as understanding the host influences beyond manufacturing.
In addition to the standard nSolver™ Analysis, genes included in the CAR-T Characterization panel are organized and linked to various advanced analysis modules to allow for efficient exploration of the eight essential aspects of CAR-T biology.
Advanced Analysis Modules available for CAR-T Characterization:
Gene Set Analysis
Built-in Compatibility for Panel Plus and Protein Analysis
TCR Diversity Score (inquire)
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
NanoString is excited to be working with Servier (as project leader), Bayer, Janssen, and Takeda as partners with the Innovative Medicines Initiative (IMI) Consortium in the European Union to develop gold standard analytical methods to use throughout development, manufacturing, and delivery of CAR-T cell therapies. The IMI is the largest public-private partnership in the world dedicated to health research.
Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing.
The majority of CD19-directed CAR T cell products are manufactured using an autologous process. Although using a patient’s leukapheresis reduces the risks of rejection, it introduces variability in starting material composition and the presence of cell populations that might negatively affect production of chimeric antigen receptor (CAR) T cells, such as myeloid cells.
Tumor interferon signaling and suppressive myeloid cells associate with CAR-T cell failure in large B cell lymphoma.
Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory large B cell lymphoma (LBCL). Here, we evaluated whether immune dysregulation, present prior to CAR-T cell therapy, associated with treatment failure.
Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood.
The ready availability of human blood makes it the first choice for immuno-monitoring. However, this has been largely confined to static metrics, particularly resting T cell phenotypes.